Press-release for stocks related to covid-19

Prices are updated after-hours

Amusement Parks Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery Analysis
Published: 2021-10-12 (Crawled : 21:00) - prnewswire.com
CMCSA | $40.26 1.62% 1.59% 24M

| -23.1% | O: 1.74% H: 0.11% C: -1.03%
covid covid-19

Pfizer-BioNTech Lead Globally with COVID-19 Vaccine
Published: 2021-10-12 (Crawled : 15:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M

| -7.7% | O: -0.16% H: 0.11% C: -1.44%
covid vaccine covid-19

LUCIRA™ HEALTH COVID-19 Test Approved for Sale in Singapore
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
LHDX | $0.4523 -10.46% 0

| -90.44% | O: -0.34% H: 3.94% C: -0.86%
covid test approval sales covid-19 health

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
IFRX | $1.36 7.94% 7.35% 140K

| -46.64% | O: 4.35% H: 0.0% C: -9.09%
covid enroll covid-19

How COVID-19 Impacted Customer Service & What's Next [Data + Expert Tips]
Published: 2021-10-12 (Crawled : 12:00) - hubspot.com
HUBS M | $631.24 -2.82% 0.09% 800K

| -7.54% | O: 1.44% H: 17.66% C: 9.49%
covid covid-19

CureVac verlagert Fokus der COVID-19-Impfstoffentwicklung auf mRNA-Technologie der zweiten Generation
Published: 2021-10-12 (Crawled : 12:00) - curevac.com
GLAXF | News | $20.2 -14.18% 510

| 3.59% | O: 3.38% H: 0.0% C: -5.75%
GSK | News | $39.75 1.22% 0.0% 1.6M

| 3.95% | O: 2.51% H: 0.15% C: -1.43%
CVAC | $2.44 0.0% 790K

| -94.35% | O: -13.04% H: 13.08% C: 9.7%
covid covid-19

CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
Published: 2021-10-12 (Crawled : 12:00) - biospace.com/
CVAC | $2.44 0.0% 790K

| -94.35% | O: -13.04% H: 13.08% C: 9.7%
covid vaccine technology covid-19

67%

33%

Save your searches and get alerts when important news are released.